Nalmefene for use in the treatment of alcohol dependence in a patient with alcohol dependence, wherein said use reduces alcohol consumption in said patient； where said patient with alcohol dependence i) has a high level of risk of alcohol consumption (DRL) corresponding to a consumption>； 60 g / day of pure alcohol for men and>； 40 g / day of pure alcohol for women, where said level of risk of alcohol consumption has been assessed by calculating the average daily consumption of alcohol in g / day during a period preceding the evaluation, where said period is 1 week or more, such as 2 weeks or more, such as 3 weeks or more, such as 4 weeks or more, such as 1 month or more, such as 2 months or more, such as 3 months or more, such as 4 months or more, such as 5 months or more , such as 6 months or more, such as about 1 year； and ii) maintains a level of risk of alcohol consumption corresponding to a consumption>； 60 g / day of pure alcohol for men and>； 40 g / day of pure alcohol for women, after an observation period of 1- 2 weeks, such as about 2 weeks after the initial evaluation； wherein said level of risk of alcohol consumption maintained is evaluated by calculating the average daily consumption of alcohol in g / day during said observation period, and wherein said nalmefene should be administered in a therapeutically effective amount； and wherein said nalmefene is administered according to needs, such as every day in which the patient perceives a risk of alcohol consumption, preferably 1-2 hours before the scheduled time of the drink.Nalmefeno para uso en el tratamiento de la dependencia del alcohol en un paciente con dependencia del alcohol, en donde dicho uso reduce el consumo de alcohol en dicho paciente； en donde dicho paciente con dependencia del alcohol i) tiene un alto nivel de riesgo de consumo de alcohol (DRL) que corresponde a un consumo >； 60 g/día de alcohol puro para los hombres y >； 40 g/día de alcohol puro para las mujeres, en donde dic
